Leerink Partners Rates Altimmune (ALT) buy, $10 Price Target

Leerink Partners reiterated its buy rating on ALT, setting a $10 price target, a 238.60% upside from the current price.

By EarningsIQ Research Desk · Published Jun 22, 2026, 11:03 AM EDT · Updated Jun 22, 2026, 9:06 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Leerink Partners rated Altimmune, Inc. ($ALT) "buy" with a $10 price target on June 22, 2026.

Since the rating, $ALT is up 0.3% after 1 week, down 4.1% after 1 month and down 24.9% to date (from the $2.93 close on Jun 22, 2026).

ALT Altimmune, Inc.

$2.20 -37.32% year to date

Daily close · Oct 16, 2026

Key Points

Leerink Partners reiterated its buy rating on ALT, setting a price target of $10 on June 22, 2026.
Leerink Partners's $10 price target implies 238.60% upside from Altimmune, Inc.'s ($ALT) current $2.95 share price.
ALT shares traded at $2.95 on Monday, with institutional investors like BlackRock and State Street increasing their holdings.
Insiders including John Gill and Diane Jorkasky bought 48,800 shares each on May 1, 2026.

Get $ALT trade alerts by text

We text you when insiders, Congress or big funds trade $ALT. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Altimmune, Inc. alert may contain errors. Disclosures

On June 22, 2026, Leerink Partners reiterated its buy rating on ALT, setting a price target of $10. This comes as ALT shares traded at $2.95 on Monday. Analyst Thomas Smith's reiteration suggests confidence in the stock's potential for growth.

Analyst rating track record

Leerink Partners vs. the S&P 500

YTD return +40.51% hypothetical

All-time return +40.51% S&P 500 +7.82%

vs. S&P 500 +32.69% ahead of the index

Hypothetical returns from Leerink Partners's disclosed trades, not real profit or advice. How we model this.

Other Institutional Activity in ALT

BlackRock, Inc. increased its holdings in ALT by 3,090,979 shares, bringing its total to 12,795,277 shares valued at approximately $39.4 million, a 31.9% increase. State Street Corp also grew its position by 2,025,847 shares, ending with 7,145,550 shares worth about $22 million, marking a 39.6% increase. Vanguard Capital Management LLC and Vanguard Portfolio Management LLC both opened new positions in ALT, with holdings of 5,658,049 and 5,382,002 shares, valued at $17.4 million and $16.6 million respectively. Marshall Wace, LLP increased its stake by 3,095,124 shares to 4,017,901 shares, a 335.4% increase, and Millennium Management LLC significantly boosted its holdings by 3,050,808 shares to a total of 3,258,191 shares, a 1471.1% increase.

Altimmune, Inc. Stock Down 9.1%

Shares of ALT traded at $2.95 on Monday. The stock has experienced various institutional interest, with major investors increasing their stakes, indicating positive sentiment. Although specific financial metrics such as market cap or P/E ratio are not available, the stock's recent trading activity reflects ongoing interest from both institutional and insider investors.

12-month forecast

$ALT price target

Altimmune, Inc. daily closes and this analyst's $10 target. Not advice.

Insider Buying and Selling at Altimmune, Inc.

On May 1, 2026, several insiders, including John Gill, Diane Jorkasky, Teri Lawver, Wayne Pisano, Philip Hodges, and Catherine Sohn, each purchased 48,800 shares of ALT. These transactions were not conducted under Rule 10b5-1 plans, signaling direct interest from these insiders.

Analysts Set New Price Targets

On June 22, 2026, Leerink Partners reiterated its buy rating on ALT with a $10 price target. Earlier, on May 18, 2026, HC Wainwright & Co. maintained its buy rating with a $20 target. Citizens also maintained a buy rating on May 14, 2026, with an $11 target. These consistent buy ratings from multiple firms suggest a positive outlook for ALT.

Bottom Line

Leerink Partners' reiteration of its buy rating on ALT with a $10 price target highlights the firm's confidence in the stock. Institutional investors have shown strong interest, with significant increases in holdings. Insider buying further supports positive sentiment, though investors should remember that analyst ratings and 13F filings are backward-looking and may not reflect current conditions.